Exploration of the DPP-4 inhibitors with a focus on saxagliptin

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 17, 2009, Pages 2927-2934

  Shubrook, Jay H ^a   Colucci, Randall A ^a   Schwartz, Frank L ^a  

^a OHIO UNIVERSITY   (United States)

Author keywords

DPP 4 inhibitors; Incretins; Insulin secretagogues; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; KETOCONAZOLE; METFORMIN; NESINA; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC PATIENT; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS;

EID: 73149105970     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903456046     Document Type: Review

References (59)

1. World Diabetes Foundation. Available from: http://www. worlddiabetesfoundation.org/ composite-35.htm [Last accessed 31 January 2009]
2. National Diabetes Information Clearinghouse. Available from: http://diabetes.niddk.nih.gov/dm/pubs/ statistics/#allages [Last accessed 31 January 2009]
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
4. Holman RR, Paul SK, Bethel MA, et al. Ten year follow up of intensive glucose control for type 2 diabetes mellitus. N Engl J Med 2008;359;15:1577-1589
5. Ohkubo Y, Kishikawa H, Raki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6 year study. Diabetes Res Clin Pract 1995;28:103-117
6. The ADVANCE Collaborative Group. Intensive blood glucose control and vascularoutcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
7. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;1:1-11
8. Grant R, Buse JB, Meigs JB, et al. Quality of diabetes care in US academic medical centers: low rates of medical regimen change. Diabetes Care 2005;28;2:337-342
9. Shah BR, Hux JE, Laupacis A. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005;28:600-606
10. Centers for Disease Control Diabetes Fact Sheet. Available from: http://www.cdc. gov/diabetes/pubs/pdf/ndfs-2007.pdf [Last accessed 31 January 2009]
11. American Diabetes Association. Costs of Diabetes Care. Available from: http://www.diabetes.org/diabetes-statistics/ cost-of-diabetes-in-us.jsp [Last accessed 31 January 2009]
12. Alexander GC, Schgal NL, Moloney RM. National trends in the treatment of type 2 diabetes: 1994 - 2007. Arch Int Med 2008;169:2088-2094
13. Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32;1:193-203
14. AACE Diabetes Mellitus Clinical Practice Guideline Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Management of Diabetes Mellitus. Endocr Pract 2007;13(Suppl 1):3-68
15. Bolen S, Feldman L, Vassy J. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Int Med 2007;147:386-399
16. Green B, Flatt P, Bailey C. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;159-165
17. Sebokova E, Christ A, Boehringer M, et al. Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. Curr Top Med Chem 2006;7:547-555
18. Ahn JH, Shin MS, Jun MA, et al. Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Bioorg Med Chem Lett 2007;17:2622-2628
19. Kuhn B, Hennig M, Mattei P. Molecular recognition of ligands in dipeptidyl peptidase IV. Curr Top Med Chem 2007;7:609-619
20. Peters JU. 11 years of cyanopyrrolidines as DPP-IV inhibitors. Curr Top Med Chem 2007;7:579-595
21. Veken PV, Haemers A, Augustyns K. Prolyl peptidase related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Top Med Chem 2007;7:621-635
22. Ferraris D, Belyakov S, Li W, et al. Azetidine-based inhibitors of dipeptidyl peptidase IV (DPP IV). Curr Top Med Chem 2007;7:597-608
23. Onglyza (saxagliptin) package insert. August 2009. Bristol-Myers Squibb/ AstraZeneca
24. Cochrane database: Available from: http://mrw.interscience.wiley.com/ cochrane-clcentral-articles-fs.html [Last accessed 31 January 2009]
25. Clinical trials.gov. Available from: http://clinicaltrials.gov/ct2/ results? term=saxagliptin [Last accessed 31 January 2009]
26. Holst JJ. Glucagon-like peptide 1(GLP-1): an intestinal hormone signaling nutritional abundance, with unusual therapeutic potential. Trends Endocrinol Metab 1999;10:229-235
27. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005;48:616-620
28. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
29. VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008;14:363-380
30. Wani JH, John-Kalarickal J, Fonseca VA. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin 2008;26:639-648
31. Miller SA, St Onge EL, Taylor JR. DPP-IV inhibitors: a review of sitagliptin, vildagliptin, alogliptin, and saxagliptin. Formulary 2008;43:122-134
32. Jadinsky M, Pfutzner A, Paz-Pacheco E, et al.; for CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622
33. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long acting, orally active dipeptidyl pepitdase IV inhibitor of type 2 diabetes. J Med Chem 2005;48:5025-5037
34. Metzler WJ, Yanchunas J, Weigelt C, et al. Involvement of DPP-IV catalytic residues in enzyme saxagliptin complex formation. Protein Sci 2008;17:240-250
35. Zhao G, Taunk PC, Magnin DR, et al. Diprolyl nitriles as potent dipeptidyl pepitase IV inhibitors. Bioorg Med Chem Lett 2005;15:3992-3995
36. Defronzo RA, Hissa M, Barber A, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655
37. Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics of a once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects [abstract 606-P]. Presented at the 67th American Diabetes Association Scientific Sessions 2007 Orlando FL, USA
38. Patel CG, Li L, Komoroski BJ, et al. No effect of saxagliptin on QTc interval in healthy subjects. American Diabetes Association Scientific Sessions 2009, New Orleans, LA
39. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin montherapy in treatment naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-2411
40. DeFronzo R, Hissa MN, Garber AJ, et al. Once-daily saxaglipitin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes mellitus. Abstract presented at the 69th Scientific Sessions of the American Diabetes Association 2009
41. Hollander P, Li J, Allen E, Chen R; for the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009, in press
42. Chen R, Dononvan M, Rusnak JM. Saxagliptin used as monotherapy or in combination with other antihyperglycemic agents does not significantly increase risk of hypoglycemia. Abstract presented at the 69th Scientific Sessions of the American Diabetes Association, 2009
43. Boulton DW, Li L, Patel CG, et al. No pharmacokinetic interaction between saxagliptin and digoxin in healthy subject. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 2-5 Apr 2008 Orlando, FL, USA. Clin Pharmacol Ther 2008;83:S93
44. Boulton DW, Goyal A, Li L, et al. The effects of age and gender on the single-dose pharmacokinetics and safety of saxagliptin in healthy subjects. Presented at 68th Scientific Sessions of the American Diabetes Association 2008;57 (S1):A164
45. Boulton DW, Tang A, Patel CG, et al. The influence of renal impairment on the pharmacokinetics of saxagliptin. Presented at American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 18-21 Mar 2009, National Harbour MD, USA. Clin Pharmacol Ther 2009;85:S96
46. Rosenstock J, Sankoh S, List JF, et al. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-386
47. Patel CG, Wolf RA, Komoroski B, et al. No meaningful pharmacokinetic drug- drug interactions between saxagliptin and pioglitazone in healthy subjects [abstract 226]. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting;14-17Oct2007,Denver,CO,USA
48. Patel CG, Li L, Komoroski B, et al. No meaningful pharmacokinetic drug-drug interactions between saxagliptin and glyburide in healthy subjects [abstract 212]. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting; 14-17 Oct 2007, Denver, CO, USA
49. Patel CG, Komoroski B, Brenner E, et al. No meaningful pharmacokinetic drug-drug interactions between saxagliptin and metformin in healthy subjects [abstract 213]. Presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting; 14-17 Oct 2007, Denver, CO, USA
50. Patel C, Castaneda L, Frevert U, et al. Single dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects [abstract 537-P]. Presented at 68th Scientific Sessions of the American Diabetes Association 2008
51. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug -naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-386
52. Pratley RE. The new science of GLP-1: effects beyond glucose control. Johns Hopkins Adv Stud Med 2008;8;393-399
53. Leiter LA. Beta-cell preservation: a potential role for thiazolidinedione to improve clinical care in type 2 diabetes. Diabet Med 2005;22:963-972
54. Viberti G, Lachin J, Holman R, et al. A diabetes outcome progression trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabet Med 2006;23:1289-1294
55. Xiang AH, Peters RK, Kjos SL, et al. Effects of pioglitazone on pancreatic B-cell function and diabetes risk in hispanic women with prior gestational diabetes. Diabetes 2006;55:517-522
56. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077
57. Wani J, John-Kalarickal J, Fonseca V. Dipeptidal peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin 2008;26:639-648
58. Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006;60:1654-1661
59. Brubaker PL, Drucker DJ. Mini review: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004;145:2653-2659